• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
7.49% $13.20

NEUREN PHARMACEUTICALS LIMITED

Market Cap $1.687B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
Broker Data - NEU 		18/01/25 7 4.2K
18/01/25 Last post  kiwig Comments Created with Sketch.  7  Views Created with Sketch.  4.2K 
NEU
Acadia
19 20 21
18/01/25 1.2K 595K
18/01/25 Last post  Tony barber Comments Created with Sketch.  1.2K  Views Created with Sketch.  595K 
NEU
Ann: Neuren JP Morgan Healthcare Conference 2025 presentation 		18/01/25 11 6.9K
18/01/25 Last post  hottod Comments Created with Sketch.  11  Views Created with Sketch.  6.9K 
NEU
Massive Equiries for NNZ-2591 		18/01/25 10 4.2K
18/01/25 Last post  royalwulff55 Comments Created with Sketch.  10  Views Created with Sketch.  4.2K 
NEU
Share Price
231 232 233
18/01/25 13K 6.5M
18/01/25 Last post  kens Comments Created with Sketch.  13K  Views Created with Sketch.  6.5M 
NEU
NEU chart
35 36 37
17/01/25 2.1K 1.1M
17/01/25 Last post  imback Comments Created with Sketch.  2.1K  Views Created with Sketch.  1.1M 
NEU
Neuren Media and Analyst Coverage
23 24 25
17/01/25 1.4K 806K
17/01/25 Last post  mickqld Comments Created with Sketch.  1.4K  Views Created with Sketch.  806K 
NEU
NEU Never Ever Understand the price vagries with this stock. 		17/01/25 3 1.5K
17/01/25 Last post  ExtraPace Comments Created with Sketch.  3  Views Created with Sketch.  1.5K 

See All Discussions arrow Created with Sketch.

Timeline

Neuren JP Morgan Healthcare Conference 2025 presentation
16 Jan 10:26
 
Trofinetide marketing application submitted in Europe
15 Jan 09:26
 
Update - Notification of buy-back - NEU
18 Dec 08:51
 
Update - Notification of buy-back - NEU
17 Dec 08:53
 
Update - Notification of buy-back - NEU
16 Dec 09:13
 
Update - Notification of buy-back - NEU
13 Dec 08:55
 
View More arrow Created with Sketch.

Featured News

NEWS Spacetalk Reports Strong Growth with $11.0 Milllion ARR
right-arrow Created with Sketch.
NEWS Hydrology Drilling Kicks Off at Lo Herma
right-arrow Created with Sketch.
NEWS Strong Sales Growth for Travelan Immune Supplement Continues
right-arrow Created with Sketch.
NEWS First Paediatric Patient Recruited for ACTION3 Phase 3 Clinical Trial
right-arrow Created with Sketch.
NEWS European Approval Granted for Prostate Cancer PET Imaging Agent Illuccix
right-arrow Created with Sketch.
NEWS Remote Medical Image Aggregation Proves Successful, Moves to Phase 2
right-arrow Created with Sketch.

(20min delay)
Last
$13.20 		Change
0.920(7.49%) 		Mkt cap ! $1.687B
Open High Low Value Volume
$12.43 $13.31 $12.42 $9.172M 706.6K

Buyers (Bids)

No. Vol. Price($)
1 7261 $13.18
 

Sellers (Offers)

Price($) Vol. No.
$13.20 13847 3
View Market Depth
Last trade - 16.10pm 17/01/2025 (20 minute delay) ?
NEU (ASX) Chart

Top Stories

Rio shares drop 1% on talk of Glencore merger

Rio Tinto has been trading down on reports that the mining titan could be in merger discussions with Glencore.
GTI progresses scoping study and other assessment work at Lo Hema GTI Energy Ltd has started drilling for the development of groundwater monitoring wells at the Lo Hema uranium project in Wyoming
Insignia Financial bags revised bid from CC Capital Insignia Financial (ASX:IFL) has received a revised non-binding and indicative proposal from CC Capital Partners.
Looking ahead to a year of intriguing investment opportunities The New Year brings renewed energy, exciting opportunities, and the promise of growth. But will the market maintain its upward momentum?
Lunnon finds shallow and broad gold with quartz breccia structure at Lady Herial Lunnon Metals Ltd has rounded off its drilling program of 2024 will a series of diamond results which showed broad gold at shallow depths

Featured News

NEWS Aussie Broadband Appoints Brian Maher as Group CEO
right-arrow Created with Sketch.
NEWS Fifth Platform Lot testing completed, 4DS advances to next stage
right-arrow Created with Sketch.
NEWS First Paediatric Patient Recruited for ACTION3 Phase 3 Clinical Trial
right-arrow Created with Sketch.
NEWS Spacetalk Reports Strong Growth with $11.0 Milllion ARR
right-arrow Created with Sketch.
NEWS Confirmation of Spodumene and High Lithium Soil Results in Brazil
right-arrow Created with Sketch.
NEWS European Approval Granted for Prostate Cancer PET Imaging Agent Illuccix
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.